Dr. Tommi Tervonen
Managing Director and Chief Scientist | Co-founder, Kielo Research | Valorem Health He has over 15 years of experience in patient preference elicitation, benefit-risk assessment, and multi-criteria decision analysis (MCDA).
About this speaker
Dr. Tervonen is a leading expert in patient preferences and benefit-risk assessment. His expertise significantly influences the opinions of decision-makers, and he has been consulted by key agencies such as the U.S. Food and Drug Administration (FDA) and the UK National Institute for Health and Care Excellence (NICE).
Dr. Tervonen leads scientific initiatives, including the ISPOR Task Force on Good Practice in Quantitative Benefit-Risk Assessment, and collaborates with experts from the FDA and the European Medicines Agency (EMA) to promote the integration of patient preferences in regulatory decision-making.
He has served as the principal investigator for numerous patient preference studies, including an industry case study for IMI PREFER, and has assisted sponsors in utilizing these study results in regulatory submissions to the EMA and FDA. Before founding Kielo Research, Dr. Tervonen led Evidera’s patient preference team and held academic positions at Erasmus University Rotterdam, Aalto University in Helsinki, and the University Medical Center Groningen.
